Article Sidebar

PDF
Date Published: 29/04/2025
Abstract Views: 148
Views PDF: 52
DOI: https://doi.org/10.51298/vmj.v550i1.13885
Issue
Vol. 550 No. 1 (2025): Vietnam Medical Journal
Section
Các bài báo
How to Cite
Thi Khanh Tuong, T. ., Thanh Duy, D. ., Duc Tien, D. ., & Nhat Huy, A. . (2025). METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN OVERWEIGHT AND OBESE VIETNAMESE. Vietnam Medical Journal, 550(1). https://doi.org/10.51298/vmj.v550i1.13885

METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN OVERWEIGHT AND OBESE VIETNAMESE

Tran Thi Khanh Tuong1,, Dao Thanh Duy1, Dao Duc Tien2, Au Nhat Huy3
1 Faculty of Medicine, Pham Ngoc Thach University of Medicine, Ho Chi Minh, Vietnam
2 Department of Gastroenterology, 175 Hospital, Ho Chi Minh, Vietnam
3 Faculty of Medicine, Tan Tao University, Ho Chi Minh, Vietnam

Main Article Content

Abstract

Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) is gradually becoming the leading cause of chronic liver disease worldwide, with its prevalence increasing due to the widespread incidence of obesity and metabolic syndrome. MAFLD has been proposed to replace the term non-alcoholic fatty liver disease (NAFLD), emphasizing the role of metabolic factors such as type 2 diabetes, hypertension, and dyslipidemia in the development and progression of liver disease. Objectives: To investigate the correlation between the degree of liver steatosis and fibrosis with BMI in patients with MAFLD. To identify the risk factors for significant liver fibrosis (F ≥ 2) in overweight and obese patients with MAFLD. Methods: The study was conducted on 192 overweight and obese patients visiting 115 People's Hospital in Vietnam from January to December 2023. Patients were evaluated using abdominal ultrasound and FibroScan to determine the degree of liver steatosis and fibrosis. Data were analyzed using SPSS software with descriptive, correlation, and regression analyses to identify risk factors. Results: The prevalence of MAFLD in the overweight and obese group was 72.92%, higher than in previous studies. There was a positive correlation between BMI and liver steatosis as well as liver fibrosis. The main risk factors for significant liver fibrosis included a high BMI (BMI ≥ 25 kg/m²) and the presence of MAFLD comorbid with other liver conditions such as chronic hepatitis B, chronic hepatitis C, and alcoholic liver disease. Conclusion: This study highlights the close correlation between BMI and the degree of liver steatosis and fibrosis in overweight and obese patients with MAFLD. The results indicate the importance of weight management and control of comorbid liver conditions to prevent the progression of liver disease in this population.

Article Details

Keywords

Metabolic dysfunction-associated fatty liver disease; MAFLD, Liver fibrosis; Liver steatosis, Overweight and obesity; FibroScan.

References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431.
2. Liu J, Ayada I, Zhang X, Li H, Zhu H, Zheng X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573-e582. doi:10.1016/j.cgh.2021.02.030.
3. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi:10.1016/j.jhep.2020.03.039.
4. Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: A meta-analysis and systematic review of 10,739,607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691-2700. doi:10.1210/clinem/dgac321.
5. Myers S, Neyroud-Caspar I, Spahr L, Radenne S, Giostra E, Frossard JL, et al. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep. 2021;3(2):100231. doi:10.1016/j.jhepr.2021.100231.
6. Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284-1291. doi:10.1016/j.jhep.2021.07.035.
7. Pinyopornpanish K, Khoudari G, Saleh MA, Alqahtani SA, Sharma P. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: A population-based study. BMC Gastroenterol. 2021;21(1):394. doi:10.1186/s12876-021-01978-0.
8. Kawaguchi T, Tsutsumi T, Nakano D, Toyoda H, Takaguchi K, Kinowaki Y, et al. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150-163. doi:10.3350/cmh.2021.0310.
9. Yamamura S, Hashimoto E, Tokushige K, Taniai M, Hashimoto Y. Study on characteristics of patients with metabolic dysfunction-associated fatty liver disease (MAFLD). J Hepatol. 2020;72(4):624-634.
10. Yuan H, Zhang X, Liu J, Li G, Wang L, Xu P, et al. Gender differences in metabolic dysfunction-associated fatty liver disease among the Asian population. Gastroenterol Res. 2019;12(2):85-95.
11. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi I, et al. Dyslipidemia in patients with metabolic-associated fatty liver disease: A meta-analysis. Hepatology. 2018;67(4):1063-1073.
12. Zysk F, Krawczyk M, Lammert F, Reeder SB, Yokoo T. Relationship between BMI and liver steatosis in MAFLD patients. J Gastroenterol Hepatol. 2019;34(9):1600-1606.
13. Gopalakrishna S, Siddiqui MS, Sterling RK, Guy CD, Mantry PS, Reuben A, et al. Fibrosis progression in metabolic-associated fatty liver disease. Liver Fibros J. 2018;25(11):1510-1522.
14. Harris R, Hood S, George J, Rowe IA. Metabolic syndrome and its contribution to liver fibrosis in patients with MAFLD. Metabolism. 2019;68(3):120-130.
15. Lee JH, Kim D, Choi SH, Chun HJ, Jung YK, Kwon HJ. Assessment of metabolic risk factors for liver fibrosis in obese populations. Clin Endocrinol (Oxf). 2019;90(1):71-78.